1. Home
  2. GMM vs BDSX Comparison

GMM vs BDSX Comparison

Compare GMM & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.28

Market Cap

38.4M

Sector

N/A

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$8.11

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
BDSX
Founded
2017
2005
Country
China
United States
Employees
N/A
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
53.0M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
GMM
BDSX
Price
$1.28
$8.11
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
17.4K
61.9K
Earning Date
08-18-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$48,171,048.00
$80,173,000.00
Revenue This Year
N/A
$19.04
Revenue Next Year
N/A
$26.39
P/E Ratio
$0.72
N/A
Revenue Growth
41.74
22.29
52 Week Low
$1.23
$3.44
52 Week High
$4.97
$32.20

Technical Indicators

Market Signals
Indicator
GMM
BDSX
Relative Strength Index (RSI) 27.84 54.30
Support Level $1.25 $7.68
Resistance Level $1.59 $8.17
Average True Range (ATR) 0.09 0.65
MACD -0.02 0.04
Stochastic Oscillator 23.08 67.36

Price Performance

Historical Comparison
GMM
BDSX

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: